FIELD: biotechnology.
SUBSTANCE: anti-Siglec-9 antibody molecules or its anti-Siglec-9 binding fragment are disclosed.
EFFECT: invention can find further application in treating cancer, acute or chronic hepatitis B.
6 cl, 9 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST SIGLEC-15 AND THEIR APPLICATION METHODS | 2017 |
|
RU2759334C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| SARS-CoV-2 ANTIBODIES AND METHODS OF USE THEREOF | 2021 |
|
RU2832025C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
